Ocugen, Inc. reports 31 percent drop in GA lesion growth with OCU410 medium dose in phase 2 trial

Ocugen, Inc. reports 31 percent drop in GA lesion growth with OCU410 medium dose in phase 2 trial
Ocugen OCU410 shows phase 2 gains

Ocugen, Inc. announced that its investigational therapy OCU410, when administered at a medium dose, led to a 31 percent reduction in geographic atrophy (GA) lesion growth in phase 2 clinical trials.

The update also indicates a 27 percent enhancement in ellipsoid zone (EZ) preservation for patients treated with the medium dose compared to control, supporting the selection of this dosage as optimal for upcoming phase 3 studies. Geographic atrophy is an advanced form of age-related macular degeneration that can result in vision loss. The latest corporate presentation on this progress is available on Ocugen, Inc.'s website.

Ocugen has accelerated development of modifier gene therapies to treat major blindness diseases, according to a previous update from the company’s pipeline initiatives (link). The company is also advancing gene therapies intended to address hundreds of mutations linked to a global vision loss burden estimated at $132 billion (link). These efforts place Ocugen among key developers in the ophthalmic gene therapy space.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.